Unlock instant, AI-driven research and patent intelligence for your innovation.

Application of biomarker scfd2 in the diagnosis and treatment of Alzheimer's disease

A material and composition technology, applied in the field of Alzheimer's diagnosis and treatment, can solve the problems of unsatisfactory sensitivity of mild dementia, mild patients with insignificant brain atrophy are not enough to provide diagnosis basis, etc.

Active Publication Date: 2020-12-25
QINGDAO MEDINTELL BIOMEDICAL CO LTD
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The commonly used clinical neuropsychological scales for evaluating cognitive function mainly include the Mini-Mental State Examination (MMSE) and the Montreal Cognitive Assessment (MoCA), but the sensitivity to mild dementia is not satisfactory (Malek-AhmadM ,Davis K,BeldenCM,et al.Comparative analysis of the Alzheimer questionnaire(AQ)with the CDRsum of boxes,MoCA,and MMSE[J].Alzheimer Dis Assoc Disord,2014,28(3):296-298.)
In the field of brain structure imaging, CT and MRI techniques can clearly show changes in brain tissue structure such as brain atrophy and ventriculomegaly, but they are not enough to provide reliable diagnostic basis for mild patients with no obvious brain atrophy (van de Pol LA, Hensel A, Barkhof F, et al.Hippoeampa latrophy in Alzheimer disease: age matters[J].Neurology,2006,66(2):236-238.)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of biomarker scfd2 in the diagnosis and treatment of Alzheimer's disease
  • Application of biomarker scfd2 in the diagnosis and treatment of Alzheimer's disease
  • Application of biomarker scfd2 in the diagnosis and treatment of Alzheimer's disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0073] Example 1 Screening for Gene Markers Related to Alzheimer's Disease

[0074] 1. Sample collection

[0075] Blood samples from 5 normal people and patients with Alzheimer's disease were collected respectively. All patients gave their informed consent, and all the above samples were obtained with the consent of the ethics committee.

[0076] 2. Preparation of RNA samples

[0077] RNA samples were extracted using Invitrogen's Blood RNA Extraction Kit. For details, see the instruction manual.

[0078] 3. Quality analysis of RNA samples

[0079] Nanodrop2000 was used to detect the concentration and purity of the extracted RNA, agarose gel electrophoresis was used to detect RNA integrity, and Agilent2100 was used to determine the RIN value. Concentration ≥ 200ng / μl, OD260 / 280 between 1.8 and 2.2.

[0080] 4. Remove rRNA

[0081] Ribosomal RNA was removed from total RNA using the Ribo-Zero kit.

[0082] 5. Construction of cDNA library

[0083] The Illumina TruseqTM RNA ...

Embodiment 2

[0090] Example 2 QPCR sequencing to verify the differential expression of the SCFD2 gene

[0091] 1. According to the detection results of high-throughput sequencing, the SCFD2 gene was selected for large-sample QPCR verification. According to the sample collection method in Example 1, 45 cases of blood from Alzheimer's patients and 45 cases of normal people's blood were selected.

[0092] 2. The RNA extraction steps are the same as in Example 1.

[0093] 3. Reverse transcription:

[0094] Take 2 μg of total RNA for reverse transcription, add 2 μl of Oligo(dT), and mix well. After bathing in water at 70°C for 5 minutes, immediately ice-bath for 2-3 minutes; continue to add 5 μl of 5× reverse transcription buffer, 5 μl of dNTP (2.5mM), 40U / μl of RNasin, 200U / μl of M-MLV, and make up to the expected volume with nuclease-free water , 42 ° C water bath for 60 minutes, 95 ° C water bath for 5 minutes to inactivate M-MLV.

[0095] 4. QPCR amplification

[0096] (1) Primer desig...

Embodiment 3

[0112] Overexpression of embodiment 3SCFD2 gene

[0113] 1. Cell culture

[0114] Dopamine neuronal cells SH-SY5Y were prepared in DMEM medium containing 10% fetal bovine serum and 1% penicillin / streptomycin (pH 7.2-7.4), at 37°C and 5% CO 2 , Cultivated in an incubator with a relative humidity of 90%. Change the medium once every 2 days, and subculture when the cells grow to 90% contact. After washing with PBS, add 0.25%-EDTA trypsin to separate the cells from the bottle wall, and terminate with DMEM medium containing fetal bovine serum. Trypsin digestion reaction, centrifuged at 1000g for 2min, discarded the supernatant, resuspended with the newly prepared culture medium, and passaged at a ratio of 1:3 to 1:4. After 24 hours, the cells entered the logarithmic growth phase and replaced the culture medium according to the experimental requirements. give different interventions.

[0115] 2. Transfection

[0116] 1) Treatment of cells before transfection

[0117] The day be...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses the application of a biomarker SCFD2 in the diagnosis and treatment of Alzheimer's disease. Through high-throughput sequencing, it is found for the first time that SCFD2 expresses down-regulation in patients with Alzheimer's disease; by up-regulating the expression level of SCFD2, the survival rate of Alzheimer's model cells can be improved, so that SCFD2 can be used as a molecular target for diagnosis and treatment of Alzheimer's disease.

Description

technical field [0001] The invention relates to the field of biotechnology, and relates to the application of SCFD2 as a molecular target in the diagnosis and treatment of Alzheimer's disease. Background technique [0002] Alzheimer's disease (AD) is a neurodegenerative disease with insidious onset and progressive development. The clinical manifestations of AD are cognitive impairment, memory function decline, abnormal behavior, visual-spatial skill impairment, and impairment of daily life (Portelius E, Zetterberg H, Skillback T, et al. Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease [J]. Brain, 2015, 138 (Pt 11): 3373-3385.). There are three stages in the clinical development of AD. The first stage is the early stage, also known as the amnestic stage. The clinical manifestations are cognitive and memory impairment, mental instability, and decreased spatial recognition ability. The initial stage generally lasts for 1-3 yea...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C12Q1/6883G01N33/68
CPCC12Q1/6883C12Q2600/136C12Q2600/158G01N33/6896G01N2333/47G01N2800/2821
Inventor 肖枫黄露宁常鹏
Owner QINGDAO MEDINTELL BIOMEDICAL CO LTD